Germany - Drugs

Description

The subject of this publication is the conclusion of contracts pursuant to Section 130a para. 8 of the German Social Code, Book V (SGB V) for the following active ingredients/active ingredient combinations within the framework of a so-called open house procedure:Acetylcysteine (R05CB01)Albendazole (P02CA03)Alitretinoin (D11AH04)Colistin (J01XB01)Flupentixol decanoate (N05AF01)Fondaparinux-Sodium (B01AX05)Fusidic Acid & Betamethasone (D07CC01)Lanreotide (H01CB03)Treprostinil (B01AC21)Subject to uniform contract conditions and a uniform access procedure, all suitable and interested pharmaceutical companies or communities of pharmaceutical companies are offered the conclusion of a rebate contract pursuant to Section 130a Para. 8 SGB V (German Social Code, Book V) for the named active ingredients/drug combinations.The earliest contract start date is July 1, 2022. Based on this, the contract term is a maximum of 24 months.
All suitable and interested pharmaceutical companies or associations of pharmaceutical companies shall be offered the conclusion of a rebate contract pursuant to Section 130a (8) SGB V for the above-mentioned active ingredients/active ingredient combinations, subject to uniform contract conditions and a uniform access procedure.The earliest contract start date is July 1, 2022. Based on this, the contract term shall be a maximum of 24 months.

Opportunity closing date

02 May 2024

Value of contract

to be confirmed